Schedule 13D ownership disclosure

Spero Therapeutics Inc

Security class unavailable · CUSIP: 84833T103

Event date: 2018-07-17

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
1,934,006
Percent of class
10.7000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000903423-18-000399
Form type
SC 13D/A
Filer
GSK plc
CIK
CIK 1131399
Filed
Jul 17, 2018
Reporting period
Jul 17, 2018
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub